Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen

BMC Cancer

Table 1 Correlations of SNCG Expression with Clinicopathologic Factors and Their Influences on Postoperative Recurrence

Characteristics	No. of cases	SNCG expression		No. of recurrence (%)	HR (95%CI)	P value
		SNCG+ (%)	P value
Gender
Male	121	38 (31.4)	0.066	28 (23.1)	1	0.205
Female	108	36 (33.3)		33 (30.6)	1.461 (0.811-2.632)
Age (yrs)
≤60	89	31 (34.8)	0.516	22 (24.7)	1	0.601
>60	140	43 (32.9)		39 (27.9)	1.176 (0.641-2.581)
Size (cm)
≤4	90	23 (25.6)	0.072	19 (21.1)	1	0.120
>4	138	51 (37.0)		42 (30.4)	1.635 (0.877-3.047)
TNM stage
I/II	114	32 (28.1)	0.172	14 (12.3)	1	0.000
III/IV	115	42 (36.5)		47 (40.9)	4.937 (2.522-9.663)
Depth of invasion
pT1 and pT2	39	12 (30.8)	0.821	4 (10.3)	1	0.011
pT3	190	62 (32.6)		57 (30.0)	3.750 (1.273-11.043)
Differentiation
WD and MD	192	61 (31.8)	0.689	49 (25.5)	1	0.384
PD	37	13 (35.1)		12 (32.4)	1.401 (0.654-2.998)
LN metastasis
Negative	125	37 (29.6)	0.336	20 (16.0)	1	0.000
Positive	104	37 (35.6)		41 (39.4)	3.417 (1.840-6.346)
Intravascular embolus
Negative	170	48 (28.2)	0.025	40 (23.5)	1	0.071
Positive	59	26 (44.1)		21 (35.6)	1.796 (0.947-3.406)
CEA
Negative	97	34 (35.1)	0.658	15 (15.5)	1	0.001
Positive	73	28 (38.4)		28 (38.4)	3.401 (1.648-7.023)
ND	59
SNCG
Negative	155	----	----	34 (22.2)	1	0.020
Positive	74	----		27 (36.5)	2.044 (1.114-3.752)

WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; LN, lymph node; HR, hazard ratio; CI, confidence interval; ND, Not Detected.

ISSN: 1471-2407